deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT03939312

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Sponsor: Allergan

Conditions Episodic Migraine
Interventions Atogepant
Updated 22 times since 2019 Last updated: Apr 19, 2022 Started: May 6, 2019 Primary completion: Mar 31, 2021 Completion: Mar 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Episodic Migraine and is currently completed. Allergan leads this study, which shows 22 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2021 — Jun 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 17 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  5. Jul 2020 — Oct 2020 [monthly]

    Enrolling By Invitation PHASE3

  6. Jun 2020 — Jul 2020 [monthly]

    Enrolling By Invitation PHASE3

  7. May 2020 — Jun 2020 [monthly]

    Enrolling By Invitation PHASE3

  8. Apr 2020 — May 2020 [monthly]

    Enrolling By Invitation PHASE3

  9. Mar 2020 — Apr 2020 [monthly]

    Enrolling By Invitation PHASE3

  10. Feb 2020 — Mar 2020 [monthly]

    Enrolling By Invitation PHASE3

  11. Dec 2019 — Feb 2020 [monthly]

    Enrolling By Invitation PHASE3

  12. Nov 2019 — Dec 2019 [monthly]

    Enrolling By Invitation PHASE3

  13. Oct 2019 — Nov 2019 [monthly]

    Enrolling By Invitation PHASE3

  14. Sep 2019 — Oct 2019 [monthly]

    Enrolling By Invitation PHASE3

  15. Aug 2019 — Sep 2019 [monthly]

    Enrolling By Invitation PHASE3

  16. Jul 2019 — Aug 2019 [monthly]

    Enrolling By Invitation PHASE3

  17. Jun 2019 — Jul 2019 [monthly]

    Enrolling By Invitation PHASE3

    First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allergan
Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Ames, United States , Amherst, United States , Anderson, United States , Atlanta, United States , Austin, United States , Aventura, United States , Baltimore, United States , Bellevue, United States and 84 more locations